Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
| Treament |
Trials |
|
|
| clinical deterioration | clinical improvement | deaths | viral clearance |
| Immunostimulants drugs | 38 | 0.56 [0.36; 0.89], 7 RCTs, I2=0% demonstrated
low degree of certainty | 1.06 [0.78; 1.45], 5 RCTs, I2=45%
inconclusive result | 1.05 [0.97; 1.13], 19 RCTs, I2=0%
inconclusive result | 6.72 [2.07; 21.82], 2 RCTs, I2=0%
moderate degree of certainty | |
| Immunosuppressants drugs | 33 | 0.79 [0.58; 1.08], 5 RCTs, I2=17%
inconclusive result | 1.28 [1.11; 1.48], 10 RCTs, I2=37% demonstrated
low degree of certainty | 0.86 [0.77; 0.97], 15 RCTs, I2=3% demonstrated
safety concern
inconclusive result | - | |
| corticosteroids | 20 | 0.70 [0.40; 1.23], 5 RCTs, I2=73%
inconclusive result | 3.34 [0.36; 30.90], 2 RCTs, I2=86%
inconclusive result | 0.93 [0.83; 1.03], 12 RCTs, I2=37% demonstrated
inconclusive result | - | |
| anti-inflammatory therapies | 5 | OBS 0.43 [0.02; 8.34], 2 studies, I2=88%
inconclusive result | OBS 12.75 [1.61; 100.79], 1 study, I2=0%
unassessable degree of certainty | OBS 0.55 [0.29; 1.03], 2 studies, I2=15%
inconclusive result | - | |
| acalabrutinib | 2 | - | - | - | - | |
| leflunomide | 1 | 1.00 [0.02; 52.54], 1 RCT, I2=0%
inconclusive result | - | 1.00 [0.02; 52.54], 1 RCT, I2=0%
inconclusive result | - | |
| A EFFACER anticorps | 0 | - | - | - | - | |
| Apilimod | 0 | - | - | - | - | |
| imatinib | 0 | - | - | - | - | |
| pirfenidone | 0 | - | - | - | - | |
| Polyinosinic-Polycytidylic Acid | 0 | - | - | - | - | |
| sargramostim | 0 | - | - | - | - | |
| thymosin | 0 | - | - | - | - | |
